Bivalirudin for Injection 250 mg, 10 Single-Dose Vials, Rx Only, Manufactured for: Accord Healthc...

FDA Recall #D-0918-2023 — Class II — July 3, 2023

Recall #D-0918-2023 Date: July 3, 2023 Classification: Class II Status: Terminated

Product Description

Bivalirudin for Injection 250 mg, 10 Single-Dose Vials, Rx Only, Manufactured for: Accord Healthcare, Inc. Durham, NC 27703 Manufactured by: Intas Pharmaceuticals Limited Ahmedabad-382 210, India, NDC 16729-275-67.

Reason for Recall

Presence of Particulate Matter: Particulate matter identified as fiber.

Recalling Firm

Accord Healthcare, Inc. — Durham, NC

Classification

Class II — May cause temporary or medically reversible adverse health consequences.

Product Type

Drugs

Product Quantity

1680 vials

Distribution

Nationwide within the United States

Code Information

Lot #: M2212070 Exp. date 08/2024

Status

Terminated

Voluntary / Mandated

Voluntary: Firm initiated